Insmed (INSM) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UBS Downgrades Insmed (INSM) to Neutral; Arikayce Becomes a 2017 Story
November 9, 2015 7:59 AM ESTUBS downgraded Insmed (NASDAQ: INSM) from Buy to Neutral with a price target of $18.00 (from $35.00) based on a SOTP as Arikayce becomes a 2017 story.
Analyst Matthew Roden commented, "Insmed reported 3Q results and an incrementally negative update to the enrollment progress... More
US NTM Delayed Up to 12 Months; Cowen Cuts Price Target on Insmed (INSM) to $34
November 9, 2015 6:46 AM ESTCowen reiterated an Outperform rating on Insmed (NASDAQ: INSM), and cut the price target to $34.00 (from $38.00), folloiwng the company's 3Q15 earnings report. INSM reported Q3 EPS of ($0.50) vs consensus ($0.47). Cowen's lower price target on INSM is based on a potential 12 month delay... More
